Amgen lifts 2026 revenue outlook, shares trade in a tight NASDAQ range

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 12:13.

Amgen Inc. (US0311621009) updated its full-year 2026 revenue guidance after reporting a stronger-than-expected first quarter, with the biotech group listed on NASDAQ adjusting its outlook to reflect robust demand for key therapies.

What the guidance shows

According to a recently updated company overview, Amgen lifted its 2026 revenue forecast to a range of 37.1 to 38.5 billion US dollars, citing Q1 performance above internal expectations. The guidance move reflects management's confidence in execution across its portfolio of oncology and inflammation treatments.

The same analysis notes that the outlook increase follows a period of marked operational focus on integrating recent acquisitions and accelerating pipeline assets into late-stage development. For investors, the higher revenue corridor provides a concrete benchmark against which to gauge subsequent quarterly results and margin trends.

Wednesday focus on operations

Beyond the guidance, Amgen's operational profile remains centered on biologic therapies and biosimilars, with manufacturing and supply chains designed to support global distribution, particularly into the US and European markets. The company continues to invest heavily in research and development, with R&D spending representing a significant share of annual revenue in recent filings.

Industry observers point out that Amgen competes with peers such as AbbVie and Bristol Myers Squibb in key therapeutic areas, where patent cycles and regulatory approvals can materially influence medium-term earnings trajectories. This competitive backdrop frames the raised 2026 revenue guidance as a step within a broader strategy to sustain growth as certain legacy products move closer to loss of exclusivity.

The product behind the stock

One of Amgen's flagship products is the osteoporosis drug Prolia (denosumab), a monoclonal antibody used to reduce fracture risk in postmenopausal women at high risk of bone loss. The therapy contributes meaningfully to the company's revenue base and illustrates its focus on biologic solutions for chronic conditions.

Where the stock trades today

Amgen shares (US0311621009) last closed on NASDAQ at 347.01 US dollars on 2026-06-23, implying a market capitalization of around 187.28 billion US dollars at that point.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources believed to be reliable but cannot be guaranteed for completeness or accuracy.